Our Mission

Cutaneous lymphomas are a diverse group of diseases that can be challenging to diagnose, are increasingly prevalent, and often lack sufficiently safe and effective treatment modalities, representing a significant unmet patient need. While many primary cutaneous lymphomas are indolent, meaning that they only show slow development or even spontaneous resolution of individual lesions, some progress to advanced-stage disease, drastically reducing the overall survival for patients affected. However, underlying mechanisms still remain only insufficiently understood. With our research, we want to better understand what makes a cutaneous lymphoma indolent vs. aggressive, and harness this information for better treatment approaches. We also want to improve diagnostic tools, as currently, it takes a median of three to six years from the first appearance of a lesion, until a proper diagnosis can be made. By studying cutaneous lymphomas, we can also learn many important aspects of overall skin immunobiology and leukocyte trafficking in this fascinating organ, to increase our general understanding of skin immune-homeostasis. Besides lymphomas, we are also interested in chronic inflammatory skin diseases such as vitiligo and atopic dermatitis, to better understand mechanisms of treatment resistance and spontaneous disease remission.